Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Pre-Mkt 06-04 04:43:37 EDT

4.43

-0.13

-2.85%

盘前4.80

+0.37+8.35%

04:01 EDT

High4.82	Low4.11	Vol43.78K
Open4.60	D1 Closing4.56	Amplitude15.61%
Mkt Cap8.90M	Tradable Cap7.29M	Total Shares2.01M
T/O190.00K	T/O Rate2.66%	Tradable Shares1.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":4.43,"timestamp":1780516800000,"preClose":4.56,"halted":0,"volume":43779,"hourTrading":{"tag":"盘前","latestPrice":4.8,"preClose":4.43,"latestTime":"04:01 EDT","volume":214,"amount":1037.40994,"timestamp":1780560074467,"change":0.37,"changeRate":0.083521,"amplitude":0},"delay":0,"changeRate":-0.02850877192982454,"floatShares":1646200,"shares":2008400,"eps":-14.79626,"marketStatus":"Pre-Mkt","change":-0.13,"latestTime":"06-04 04:43:37 EDT","open":4.6,"high":4.8217,"low":4.11,"amount":189995.869194,"amplitude":0.156075,"askPrice":5.21,"askSize":100,"bidPrice":4.12,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-14.79626,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780579800000},"marketStatusCode":1,"adr":0,"adrRate":35,"exchange":"NASDAQ","adjPreClose":4.43,"preHourTrading":{"tag":"盘前","latestPrice":4.8,"preClose":4.43,"latestTime":"04:01 EDT","volume":214,"amount":1037.40994,"timestamp":1780560074467,"change":0.37,"changeRate":0.083521,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.3428,"preClose":4.43,"latestTime":"17:01 EDT","volume":1001,"amount":4347.2,"timestamp":1780520481326,"change":-0.0872,"changeRate":-0.019684,"amplitude":0},"volumeRatio":1.1572887004692123},"requestUrl":"/m/hq/s/QNRX","defaultTab":"news","newsList":[{"id":"2640894906","title":"Quoin Pharmaceuticals submits QRX003 IND application to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640894906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640894906?lang=en_us&edition=fundamental","pubTime":"2026-06-02 22:36","pubTimestamp":1780410980,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced the submission of an investigational new drug, or IND, application to the FDA for QRX003 for the treatment o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-submits-qrx003-ind-application-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-submits-qrx003-ind-application-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IND","BK4139","BK4588","QNRX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640480899","title":"Quoin Pharmaceuticals submits FDA IND for QRX003 in Peeling Skin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2640480899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640480899?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:32","pubTimestamp":1780403571,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals submitted an FDA IND for QRX003 to treat Peeling Skin Syndrome, a rare disease with no approved therapy.FDA review is pending; a Phase 2 study is targeted for the second half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7Gx8gC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4585","IE00BN0W2T93.GBP","BK4112","QNRX","SG9999014005.SGD","LU2210149790.SGD","SG9999014013.SGD","BK4588","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634028468","title":"Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634028468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634028468?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:55","pubTimestamp":1778255718,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Naz Rahman reiterated a Buy rating on Quoin Pharmaceuticals yesterday and set a price target of $40.00. Rahman covers the Healt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/quoin-pharmaceuticals-qnrx-receives-a-buy-from-maxim-group-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/quoin-pharmaceuticals-qnrx-receives-a-buy-from-maxim-group-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633314243","title":"Quoin Pharmaceuticals Q1 EPS $(1.77) Misses $(1.72) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633314243","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633314243?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:32","pubTimestamp":1778157167,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.72) by 2.91 percent. This is a 72.77 percent increase over losses of $(6.50) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52364293/quoin-pharmaceuticals-q1-eps-1-77-misses-1-72-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914226","title":"Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914226","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914226?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:30","pubTimestamp":1778157000,"startTime":"0","endTime":"0","summary":"– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome  – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290007/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ODD","QNRX","IE0009354923.USD","BK4183","BK4585","BK4588","LABU","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633949173","title":"Quoin Pharmaceuticals Ltd  expected to post a loss of $1.93 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633949173","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633949173?lang=en_us&edition=fundamental","pubTime":"2026-05-05 22:33","pubTimestamp":1777991584,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd  expected to post a loss of $1.93 a share - Earnings Preview Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to  show no change in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I27C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633957554","title":"Quoin Pharmaceuticals Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2633957554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633957554?lang=en_us&edition=fundamental","pubTime":"2026-05-05 01:13","pubTimestamp":1777914780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 13:13 ET (17:13 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632932880","title":"Quoin Pharmaceuticals initiated with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2632932880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632932880?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:11","pubTimestamp":1777889474,"startTime":"0","endTime":"0","summary":"Lucid Capital initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $30 price target Quoin is a late-stage clinical specialty ph...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-initiated-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-initiated-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4596","LCIZ","BK4555","BK4099","BK4551","LCDL","QNRX","LCID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631163275","title":"Quoin Pharma to report Q1 results, provide corporate update May 7","url":"https://stock-news.laohu8.com/highlight/detail?id=2631163275","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631163275?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:33","pubTimestamp":1777552399,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals will release first-quarter 2026 financial results before market open on Thursday, May 7, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL53lGLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","BK4139","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","QNRX","LU2210149790.SGD","SG9999014013.SGD","BK4585","BK4112","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630588449","title":"Quoin Pharmaceuticals Provides Clinical And Regulatory Update For Qrx009 Topical Rapamycin Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2630588449","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630588449?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:55","pubTimestamp":1777384522,"startTime":"0","endTime":"0","summary":"April 28 (Reuters) - Quoin Pharmaceuticals Ltd <2EB0y.F>::*QUOIN PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE FOR QRX009 TOPICAL RAPAMYCIN DEVELOPMENT PROGRAMS*QUOIN PHARMACEUTICALS LTD - T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nRSD2DHyyQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630047183","title":"Quoin plans investigator-led trial of QRX009 topical rapamycin in pachyonychia congenita","url":"https://stock-news.laohu8.com/highlight/detail?id=2630047183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630047183?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:35","pubTimestamp":1777379739,"startTime":"0","endTime":"0","summary":"Quoin outlined plans to launch several investigator-led clinical studies for QRX009 topical rapamycin, with no trial results presented to date.First study targets pachyonychia congenita, with initiation targeted for Q3 2026.Additional investigator-led studies in Gorlin syndrome and tuberous sclerosis complex are planned later in 2026 to broaden QRX009 clinical readouts.Regulatory strategy includes filing an FDA investigational new drug application for QRX009 in an additional indication in Q3 2026.Management expects QRX009 could be in active testing across four indications before end-2026, positioning it as a pipeline expansion alongside ongoing late-stage work in Netherton syndrome.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL8rmx47:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630472304","title":"Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2630472304","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630472304?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:30","pubTimestamp":1777379400,"startTime":"0","endTime":"0","summary":"Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications.  Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/28/3282671/0/en/Quoin-Pharmaceuticals-Provides-Clinical-and-Regulatory-Update-for-QRX009-Topical-Rapamycin-Development-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","LU2237438978.USD","BK4504","LU2750360997.AUD","LU1868837300.USD","LU2265009873.SGD","LU1868837136.USD","LU2750360641.GBP","IE00B19Z3B42.SGD","LU2237443622.USD","LU0048573561.USD","LU0061475181.USD","LU2237443382.USD","LU2237443549.SGD","BK4585","GSX","BK4127","IE00B19Z3581.USD","LU1894683348.USD","IE00BFXG1179.USD","BK4550","LU1868836914.USD","IE0004091025.USD","LU2237443978.SGD","QNRX","BK4588","BK4552","BK4533","LU0345770993.USD","BK4139","LU1894683264.USD","IND","LU2471134879.HKD","LU2471134796.USD","LU1804176565.USD","IE00BSNM7G36.USD","LU0251142724.SGD","LU2471134952.CNY","LU1868836591.USD","BK4516","BK4209","LU0251131958.USD","LU0106831901.USD","LU2237443895.HKD","PC","LU0345770308.USD","IE0004086264.USD","LU1791807156.HKD","IE0034235188.USD","LU1668664300.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629005608","title":"Quoin’s QRX003 Trial Moves Forward In Rare Skin Disease, Keeping QNRX On Investor Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2629005608","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629005608?lang=en_us&edition=fundamental","pubTime":"2026-04-22 00:31","pubTimestamp":1776789083,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd ($QNRX) announced an update on their ongoing clinical study. The multicenter study “A Multicenter, Open-label Study of QR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoins-qrx003-trial-moves-forward-in-rare-skin-disease-keeping-qnrx-on-investor-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoins-qrx003-trial-moves-forward-in-rare-skin-disease-keeping-qnrx-on-investor-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622961388","title":"Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=2622961388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622961388?lang=en_us&edition=fundamental","pubTime":"2026-03-28 14:00","pubTimestamp":1774677650,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Debt & Financing category. Quoin Pharmaceuticals Ltd. faces heightened financing ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/financing-covenants-put-quoin-pharmaceuticals-at-heightened-risk-of-funding-shortfall-and-program-delays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/financing-covenants-put-quoin-pharmaceuticals-at-heightened-risk-of-funding-shortfall-and-program-delays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622082337","title":"Quoin Pharmaceuticals Ltd : Alliance Global Partners Raises Target Price to $35 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2622082337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622082337?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:03","pubTimestamp":1774609386,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622866806","title":"Quoin Pharmaceuticals Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622866806","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622866806?lang=en_us&edition=fundamental","pubTime":"2026-03-26 22:09","pubTimestamp":1774534181,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd reports results for the quarter ended December 31 - Earnings SummaryQuoin Pharmaceuticals Ltd QNRX.OQ reported a quarterly adjusted loss of $14.80 per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E1FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622985779","title":"Quoin Pharmaceuticals Q4 EPS $(1.74) Beats $(4.02) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622985779","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622985779?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:32","pubTimestamp":1774528331,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of $(4.02) by 56.72 percent. This is a 85.96 percent increase over losses of $(12.39) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51479392/quoin-pharmaceuticals-q4-eps-1-74-beats-4-02-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622570558","title":"Quoin Pharmaceuticals FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622570558","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622570558?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:31","pubTimestamp":1774528291,"startTime":"0","endTime":"0","summary":"Quoin published a press release providing a corporate update and reporting fourth-quarter and full-year 2025 financial results.Net loss widened to USD 4.3 million in Q4 2025, and to USD 15.8 million for FY 2025.Research and development expense rose to USD 9.8 million for FY 2025, nearly tripling, while general and administrative expense increased to USD 6.5 million, up 9.5%.Cash, cash equivalents and marketable securities totaled USD 18.7 million at year-end 2025, and Quoin said this is expected to fund operations into 2027.Michael Myers said the company is preparing to initiate a Phase 3 study for QRX003 in Netherton syndrome in 2026 and is targeting an NDA filing in 2027, with topline data from two whole-body Netherton syndrome trials expected in the second half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL64PZGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","BK4588","LU2210150020.SGD","IE00BN0W2T93.GBP","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4112","BK4139","IE00BN0W2V16.EUR","QNRX","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622857777","title":"Press Release: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622857777","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622857777?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:30","pubTimestamp":1774528200,"startTime":"0","endTime":"0","summary":"-- Closes Private Placement Financing of Up to $104.5 Million. -- Secures Orphan Drug Designations for QRX003 for Netherton Syndrome  in the U.S. and Europe. -- Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designation in the U.S. for QRX003 for NS Subsequent to the End of Q4. -- Reports Continued Clinical Progress for QRX003 in Netherton Syndrome Clinical Studies including Data Supporting Longer Term Durable Treatment Effect and Safety Profile. -- Pediatric NS Study Expanded to 7 Children Now Actively Treated with QRX003, Largest Cohort of This Age Group Ever Studied. -- Ongoing Clinical Data Continues to Support Development of QRX003 as a Treatment for Peeling Skin Syndrome with Study Being Expanded to 6 Subjects. -- Proprietary Rapamycin Topical Platforms Achieve Target Loadings; Clinical Studies Planned in 2H 2026. -- NETHERTON NOW Awareness Campaign Surpasses 2 Million Video Views and 24 Million Global Impressions. ASHBUR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4585","LABU","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851232","title":"Market Sentiment Around Loss-Making Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851232","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851232?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:14","pubTimestamp":1774520089,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals, Ltd. ( NASDAQ:QNRX ) is possibly approaching a major achievement in its business, so we would...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qnrx/quoin-pharmaceuticals/news/market-sentiment-around-loss-making-quoin-pharmaceuticals-lt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qnrx/quoin-pharmaceuticals/news/market-sentiment-around-loss-making-quoin-pharmaceuticals-lt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GPIQ","NQmain","QNRX","SQQQ","QQQJ","BK4139","NVIW.SI","QID","PSQ","TQQQ","QLD","QQQE","QYLG","JEPQ",".IXIC","MNQmain","QQQY","QDTE","IYW","FTEC"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":-0.114},{"period":"1month","weight":-0.3035},{"period":"3month","weight":-0.4831},{"period":"6month","weight":-0.6336},{"period":"1year","weight":-0.5061},{"period":"ytd","weight":-0.693}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":0.0505},{"period":"3month","weight":0.107},{"period":"6month","weight":0.1},{"period":"1year","weight":0.2653},{"period":"ytd","weight":0.1061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.264124},{"month":2,"riseRate":0.2,"avgChangeRate":-0.199382},{"month":3,"riseRate":0.2,"avgChangeRate":-0.222445},{"month":4,"riseRate":0.2,"avgChangeRate":-0.15112},{"month":5,"riseRate":0.4,"avgChangeRate":-0.043514},{"month":6,"riseRate":0.4,"avgChangeRate":-0.082225},{"month":7,"riseRate":0.5,"avgChangeRate":-0.033987},{"month":8,"riseRate":0.5,"avgChangeRate":-0.098098},{"month":9,"riseRate":0,"avgChangeRate":-0.208503},{"month":10,"riseRate":0.5,"avgChangeRate":0.22434},{"month":11,"riseRate":0.4,"avgChangeRate":0.035616},{"month":12,"riseRate":0.2,"avgChangeRate":-0.187047}],"exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals","securityTypeName":"DR","adrRate":"1:35"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}